CEO David Hallal shared with CNBC how ElevateBio is disrupting the industry by offering partners an integrated tech stack with end-to-end manufacturing through its genetic medicine foundry model. Watch his full interview at https://lnkd.in/eACRdDps.
ElevateBio
Biotechnology Research
Waltham, Massachusetts 33,434 followers
A cell and gene therapy company accelerating access to technologies and expertise to change the future of medicine.
Über uns
ElevateBio is a technology-driven company built to power transformative genetic medicines today and for many decades to come. The Company commercializes its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate development across a breadth of therapeutic approaches and modalities. The ElevateBio ecosystem combines multiple R&D technology platforms – including Life Edit, a next-generation, full-spectrum gene editing platform; comprehensive cell engineering technologies; and an expanded viral and non-viral therapeutic delivery platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to accelerate the discovery and development of advanced therapeutics. ElevateBio aims to be the dominant engine inside the world’s greatest scientific advancements harnessing human cells and genes to alter disease.
- Website
-
https://www.elevate.bio/
External link for ElevateBio
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Waltham, Massachusetts
- Typ
- In Privatbesitz
- Spezialitäten
- cell therapy, gene therapy, and cell and gene therapy
Standorte
-
Primäre
Wegbeschreibung erhalten
200 Smith St
Waltham, Massachusetts 02451, US
Employees at ElevateBio
Aktualisierungen
-
Base editing is a method of gene editing that converts one nucleotide base into another without the need to cut both strands of DNA. Life Edit Therapeutics's PAM diversity enables base editing at more sites, allowing for the potential to make any edit anywhere in the genome and correct genetic mutations linked to diseases. #BaseEditing #PAMs
-
-
We offer our partners unmatched industry-leading expertise in product development. Our tools, resources and expertise ensure seamless transitions from concept to commercialization. We’re here to support you at any stage of your journey. Explore our end-to-end capabilities: https://lnkd.in/epnCHZu2.
-
-
Congratulations to the Abata Therapeutics team on this significant milestone! We are proud to be partnering on the advancement of ABA-101 for the treatment of people living with progressive multiple sclerosis.
The FDA Fast Track designation for ABA-101 for the treatment of progressive multiple sclerosis will enable us to expedite our efforts to bring ABA-101 to patients. This designation advances our mission, as initiation of a first-in-human (FIH) Phase 1 study is imminent. #clinicaltrials #drugdevelopment #MS https://bit.ly/4dWJrOZ
-
-
Designed to be readily accessible to patients, allogeneic cell therapy is an ‘off-the-shelf’ form of immunotherapy. Cells are taken from cell lines or health donors and engineered for on demand treatments. We’re leveraging our knowledge across gene editing and cell and vector engineering to optimize cells for this therapeutic approach. #AllogeneicCellTherapy #CellTherapy
-
-
We offer unmatched flexibility in three types of gene editing: double-strand breaks, base editing, and reverse transcriptase (RT) editing. Life Edit Therapeutics diverse collections of Protospacer Adjacent Motifs (PAMs) enable broad access to the genome, making any edit anywhere possible. This unprecedented access unlocks new possibilities for addressing a wide range of diseases and disorders. #PAMDiversity #ElevateBio #GeneticMedicines
-
-
To change the future of medicine, we're breaking boundaries and stepping into tomorrow. By harnessing the power of artificial intelligence, we’re accelerating the discovery and engineering of life-saving therapies for the most serious diseases. Join the expedition: https://lnkd.in/e8PRHJnj. #CRISPR #AI #ElevateBio
-
BaseCamp’s proprietary LentiPeak™ lentiviral vector platform is customizable to meet your development needs– offering speed, control strategies, and flexibility. Our end-to-end support and unmatched expertise has you covered from start to finish. Learn more: https://lnkd.in/ed8fRD-F.
-
Be part of advancing transformative therapies. ElevateBio is seeking a Site Head for our new BaseCamp biomanufacturing facility in Pittsburgh, located in Hazelwood Green. ElevateBio is proud to bring cutting-edge technologies, expertise, and workforce expansion to a city ready to take part in leading the life sciences industry. Learn more about the position here: https://lnkd.in/eQ-ZYNhi. #ElevateBio #NowHiring
-
-
Life Edit’s platform supports a variety of gene editing modalities, including gene knock-ins and knock-outs, base editing, and reverse transcriptase (RT) editing. Our libraries of RNA-guided nucleases (RGNs) are smaller in size, offering greater versatility and delivery. Rewrite the future of genetic medicine with us. Explore limitless gene editing: https://lnkd.in/e8PRHJnj. #GeneEditing #ElevateBio
-